Zobrazeno 1 - 1
of 1
pro vyhledávání: '"T. Z. Jodlowski"'
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 42:115-118
SummaryWhat is known and objective Paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) is a direct-acting antiviral (DAA) approved for the treatment of chronic hepatitis C virus. We report on a probable interaction between PrOD with ribavirin and warf